<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <link rel="stylesheet" href="https://maxcdn.bootstrapcdn.com/bootstrap/4.0.0/css/bootstrap.min.css"
        integrity="sha384-Gn5384xqQ1aoWXA+058RXPxPg6fy4IWvTNh0E263XmFcJlSAwiGgFAW/dAiS6JXm" crossorigin="anonymous">
    <script src="https://code.jquery.com/jquery-3.2.1.slim.min.js"
        integrity="sha384-KJ3o2DKtIkvYIK3UENzmM7KCkRr/rE9/Qpg6aAZGJwFDMVNA/GpGFF93hXpG5KkN"
        crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/popper.js/1.12.9/umd/popper.min.js"
        integrity="sha384-ApNbgh9B+Y1QKtv3Rn7W3mgPxhU9K/ScQsAP7hUibX39j7fakFPskvXusvfa0b4Q"
        crossorigin="anonymous"></script>
    <script src="https://maxcdn.bootstrapcdn.com/bootstrap/4.0.0/js/bootstrap.min.js"
        integrity="sha384-JZR6Spejh4U02d8jOt6vLEHfe/JQGiRRSQQxSfFWpi1MquVdAyjUar5+76PVCmYl"
        crossorigin="anonymous"></script>
    <link rel="stylesheet" href="css/T--AFCM-Egypt--style.css">
    <link rel="stylesheet" href="https://stackpath.bootstrapcdn.com/font-awesome/4.7.0/css/font-awesome.min.css">
    <title>Document</title>
</head>

<body>
    <div class="row">
        <div class="col-md-2">
            <div class="navbar-inverse navbar-fixed-left">
                <ul class="side-nav-items py-5 px-2">
                    <a href="#description">
                        <li>
                            Description
                        </li>
                    </a>
                    <a href="#rationale">
                        <li>
                            Dataset Gathering
                        </li>
                    </a>
                    <a href="#dataset">
                        <li>
                            Dataset Gathering
                        </li>
                    </a>
                    <a href="#dnaVaccine">
                        <li>
                            DNA vaccine circuit
                        </li>
                    </a>
                    <a href="#methodology">
                        <li>
                            Methodology Guidelines
                        </li>
                    </a>
                    <a href="#conclusion">
                        <li>
                            Conclusion
                        </li>
                    </a>
                </ul>
            </div>
        </div>
        <div class="col-md-10">
            <nav class="navbar navbar-expand-lg pl-4 pt-3 pr-4 mb-5 container">
                <button class="navbar-toggler" type="button" data-toggle="collapse"
                    data-target="#navbarSupportedContent" aria-controls="navbarSupportedContent" aria-expanded="false"
                    aria-label="Toggle navigation">
                    <img class="navbar-toggler-icon d-inline"
                        src="https://2020.igem.org/wiki/images/d/d3/T--AFCM-Egypt--navbarbutton.jpeg" alt="">
                </button>

                <div class="collapse navbar-collapse" id="navbarSupportedContent">
                    <ul class="navbar-nav ml-auto">
                        <li class="nav-item active">
                            <a class="nav-link" href="/">Home <span class="sr-only">(current)</span></a>
                        </li>
                        <li class="nav-item dropdown">
                            <a class="nav-link dropdown-toggle" href="#" id="navbarDropdown" role="button"
                                data-toggle="dropdown" aria-haspopup="true" aria-expanded="false">
                                Team
                            </a>
                            <div class="dropdown-menu" aria-labelledby="navbarDropdown">
                                <a class="dropdown-item" href="team.html">Team members</a>
                                <a class="dropdown-item" href="#">Attributions</a>
                            </div>
                        </li>
                        <li class="nav-item dropdown">
                            <a class="nav-link dropdown-toggle" href="#" id="navbarDropdown" role="button"
                                data-toggle="dropdown" aria-haspopup="true" aria-expanded="false">
                                Project
                            </a>
                            <div class="dropdown-menu" aria-labelledby="navbarDropdown">
                                <a class="dropdown-item" href="#">Description</a>
                                <a class="dropdown-item" href="#">Engineering</a>
                                <a class="dropdown-item" href="#">Contribution</a>
                                <a class="dropdown-item" href="#">Implementation</a>
                                <a class="dropdown-item" href="#">Entrepreneurship</a>
                                <a class="dropdown-item" href="#">Modeling</a>
                            </div>
                        </li>
                        <li class="nav-item dropdown">
                            <a class="nav-link dropdown-toggle" href="#" id="navbarDropdown" role="button"
                                data-toggle="dropdown" aria-haspopup="true" aria-expanded="false">
                                Parts
                            </a>
                            <div class="dropdown-menu" aria-labelledby="navbarDropdown">
                                <a class="dropdown-item" href="#">Basic Parts</a>
                                <a class="dropdown-item" href="#">Composite Parts</a>
                            </div>
                        </li>
                        <li class="nav-item">
                            <a class="nav-link" href="#">Software</a>
                        </li>
                        <li class="nav-item dropdown">
                            <a class="nav-link dropdown-toggle" href="#" id="navbarDropdown" role="button"
                                data-toggle="dropdown" aria-haspopup="true" aria-expanded="false">
                                Human Practices
                            </a>
                            <div class="dropdown-menu" aria-labelledby="navbarDropdown">
                                <a class="dropdown-item" href="#">Human Practices</a>
                                <a class="dropdown-item" href="#">Education</a>
                                <a class="dropdown-item" href="#">Collaboration</a>
                                <a class="dropdown-item" href="#">Partnership</a>
                            </div>
                        </li>
                    </ul>
                </div>
            </nav>
            <main class="py-5 container">
                <h1>Project Description</h1>
                <section id="description" class="d-flex flex-column align-items-center my-5">
                    <p>In Egypt, breast cancer is the most prevalent malignancy and leading cause of cancer death among
                        women around the world. According to Globocan 2018, the number of new cancer cases is 128892
                        which represents a percentage of <b>0.1297%</b> of the total population. In both sexes and all
                        ages,
                        the number of new breast cancer cases is 23081 with a percentage of <b>(17.9%)</b> of total
                        cancer
                        cases as it lies in the second rank of the most incident cancers in Egypt after liver cancer as
                        shown in Graph (1). The number of new cases among females is 23081 with a percentage of 35.1% of
                        total cancers among females as illustrated in Graph <strong>(2).(1),(3)</strong>
                    </p>
                    <img src="https://2020.igem.org/wiki/images/8/88/T--AFCM-Egypt--description-graph1.png" width="80%"
                        class="my-4" style="opacity: .89;" alt="">
                    <p>
                        Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer that does not
                        express the genes for estrogen receptor (ER), progesterone receptor (PR) and HER2/neu.(2). To
                        get to know all the most common neoantigens related to TNBC in Egypt, we started by Dataset for
                        all Cancer-Associated Antigens (TAAs). Neoantigens related to breast cancer were then selected
                        and filtered to obtain a new dataset of neoantigens expressed specifically in TNBC which were
                        then compared to the Egyptian population.
                    </p>
                    <p>
                        DNA Vaccination is a direct insertion of a plasmid containing a DNA sequence encoding the
                        antigen(s) to which the immune response is obtained and depending on the in-situ generation of
                        the target antigen into the appropriate tissues. This approach provides many possible advantages
                        compared with conventional approaches, including activation of both B- and T-cell responses,
                        increased vaccine safety, absence of any infectious agent and relative ease of manufacturing on
                        a wide scale. That is why the team is concerned with innovating a multi-epitope DNA vaccine for
                        TNBC. <b>(4),(5),(6)</b>
                    </p>
                    <p class="font-weight-bold text-danger">
                        Notice: parts in our range for this season have been created as a part of our Phase I design of
                        our project. These parts HAVE NOT been tested or characterized in the lab due to
                        COVID-19-related precautionary measures. We have enriched our new parts pages with data from
                        literature and results from our modeling and simulations. If you are intending on using this
                        part or others in our range, please keep in mind these limitations and update these parts with
                        data from your experimentation. Feel free to reach us at: igem.afcm@gmail.com for further
                        inquiries.
                    </p>
                </section>
                <section id="rationale" class="d-flex flex-column align-items-center my-5">
                    <h2>Rationale</h2>
                    <p>
                        Immunotherapy is a promising alternative for traditional chemotherapies and treatment options
                        for

                        triple-negative breast cancer.(28)

                        Continuous Ongoing studies and clinical trials may show more evidence for the effectiveness of
                        Immunotherapeutic approaches. Immunotherapy can be very expensive we are talking about costs
                        that may reach over than $100,000 per year is frequently secured by health insurance, but
                        patients still need to deal with Surgery and other cancer medications which add more to the
                        financial predicament of rising out-of-pocket costs.(23)
                    </p>
                    <h3>Reason behind choosing Breast cancer, and why TNBC in particular?</h3>
                </section>
                <section id="dataset" class="d-flex flex-column align-items-center my-5">
                    <h2>Dataset gathering
                    </h2>
                    <p>
                        TNBC Patients' DNA sequences were retrieved from NCBI database consequently, all the candidate
                        epitopes were analysed using Custommune analysis tools then filtered and Screened for highly
                        ranked recognition score by multiple HLA alleles. Eventually, we Perform docking (DFIRE score)
                        of the HLA-epitope binding to provide a final antibody epitope prediction. <b>(7)</b>
                    </p>
                    <img src="https://2020.igem.org/wiki/images/e/e8/T--AFCM-Egypt--description-dataGathering.png"
                        width="80%" class="my-4" style="opacity: .89;" alt="">
                </section>
                <section id="dnaVaccine" class="d-flex flex-column align-items-center my-5">
                    <h2>DNA vaccine circuit
                    </h2>
                    <p>
                        Multi-epitope DNA vaccine to combat the TNBC is designed using immunoinformatics approach,
                        through the fusion of multiple dendritic cell epitopes presenting them to CD4 (+) T cells that
                        once become activated will produce cytokines and can help activate antibody producing B cells,
                        therefore Dendritic cells sequester antigenic epitopes acting as a bridge between innate and
                        adaptive immunity, helper, cytotoxic and B-cell epitopes and adjuvant.<b>(8),(9),(10)</b>. These
                        crucial components of the newly constructed TNBC DNA vaccine were conjugated using proper
                        Linkers as simulated in fig (1). This vaccine was subsequently tested for different
                        physicochemical characteristics and examined by molecular dynamics simulation tools for
                        structure refinement, safety insurance, efficacy, and Validity.

                    </p>
                    <img src="https://2020.igem.org/wiki/images/c/c7/T--AFCM-Egypt--description-DNACircuit.png"
                        width="80%" class="my-4" style="opacity: .89;" alt="">
                </section>
                <section id="methodology" class="d-flex flex-column align-items-center my-5">
                    <h2>Methodology Guidelines
                    </h2>
                    <p>
                        This year, our team is creating novel DNA vaccination platform aims as an enhanced
                        immunotherapeutic approach targeting (<strong><em>TNBC</em></strong>) using a combination of
                        neatly selected multiple
                        neo-epitopes conjugated using proper linkers that were optimized according to certain linker
                        selection parameters constructing a SynBio design that relies on natural self-replicating viral
                        abilities of RNA replicons delivered in logically optimized DNA circuits, therefore creating a
                        DNA-launched RNA Replicons (<strong><em>DREP</em></strong>).<b>(13)</b>
                    </p>
                    <p>
                        The platform utilizes the inherent self-amplification ability of RNA-replicons to ensure
                        enhanced neo-antigen uptake and presentation leading to the mounting of efficient cellular and
                        humoral immune responses against TNBC. Embedded with optimized subgenomic regulation and
                        linker-peptides alongside glycine-alanine repeats (GAr), a miRNA-based immune evasion mechanism
                        and an OFF-switch, our platform is predicted to be highly safe and efficient through
                        experimentally-driven mathematical simulations.<b>(14),(15)</b>.
                    </p>
                    <p>
                        Immune-modulating adjuvant (<strong><em>Beta-Defensin</em></strong>), Pan HLA-DR epitopes
                        (<strong>PADRE</strong>) and Heat Shock protein
                        (<strong>HSP</strong>) sequence were also added with epitopes sequence to enhance the
                        immunogenicity. All the
                        epitopes, adjuvants and PADRE sequence were joined by linkers. In the construction of
                        multiepitope vaccines <strong>EAAK linker</strong> is found to increase stability and reduce
                        connection with
                        other protein areas with efficient detachment. There is a possibility that the immunogenicity
                        could increase with an adjuvant. Based on the interactions’ compatibility HTL, CTL and B-Cell
                        epitopes were merged together sequentially with <strong>GPGPG, AAY</strong> and
                        <strong>KK</strong> linkers, respectively. <b>(16)</b>
                    </p>
                    <p>
                        Mathematical modelling-based simulation proofed potential therapeutic immunity of our approach.
                        Eventually, our vaccine will be sequestered by DCs to present the hotspots of epitopes predicted
                        by Custommune to CTLs and T-Helper cells that once become activated, will produce cytokines and
                        activate antibody producing B cells, thus acting as a bridge between innate and adaptive immune
                        response to combat TNBC. <b>(17)</b>

                        Using various sets of computational validation tools, we were able to assess the immunogenicity
                        of our final proposed Vaccine models.
                    </p>
                    <img src="https://2020.igem.org/wiki/images/1/17/T--AFCM-Egypt--description-guideline.png"
                        width="80%" class="my-4" style="opacity: .89;" alt="">
                </section>

                <section id="conclusion" class="d-flex flex-column align-items-center my-5">
                    <h2>
                        Conclusion
                    </h2>
                    <p>
                        Narrowing the scope to choose the frequent neoepitopes in Egyptian patients with TNBC shows that
                        there is no need for the traditional methods of whole exome sequencing to save money and time.
                        In addition to the advantages in using them in <b>Multi-epitope DNA-replicon based vaccine</b>
                        which
                        has a significant therapeutic role in stimulating the immune response to the neoplastic cells
                        and linking between innate and adaptive immune system through presenting the antigen on DCs
                        surface which activates the adaptive immune system especially CTLs.


                    </p>
                </section>
                <section id="literature" class="d-flex flex-column align-items-center my-5 resources">
                    <h2>
                        Literature Cited
                    </h2>
                    <ol>
                        <li>
                            <p>
                                World Health Organization. Global Health Observatory. <br> Geneva: World Health
                                Organization;
                                2018. who.int/gho/database/en/. Accessed June 21, 2018.
                            </p>
                        </li>
                        <li>
                            <p>
                                Uscanga-Perales, G., Santuario-Facio, S., & Ortiz-López, R. (2016, October 19). Triple
                                negative breast cancer: Deciphering the biology and heterogeneity. Retrieved October 25,
                                2020, from https://www.sciencedirect.com/science/article/pii/S1665579616300667
                            </p>
                        </li>
                        <li>
                            <p>
                                Ferlay J, Colombet M, Soerjomataram Iet al. Global and Regional Estimates of the
                                Incidence and Mortality for 38 Cancers: GLOBOCAN 2018. Lyon: International Agency for
                                Research on Cancer/World Health Organization; 2018.
                            </p>
                        </li>
                        <li>
                            <p>
                                Thun MJ, Henley SJ, Travis WD. Lung cancer. In: Thun MJ, Linet MS, Cerhan JR, Haiman CA,
                                Schottenfeld D, eds. Cancer Epidemiology and Prevention. 4th ed. New York, NY: Oxford
                                University Press; 2018:519‐542.
                            </p>
                        </li>
                        <li>
                            <p>
                                Garmory HS, Brown KA, Titball RW. DNA vaccines: improving expression of antigens.
                                Genetic vaccines and therapy. 2003 Dec 1;1(1):2.
                            </p>
                        </li>
                        <li>
                            <p>
                                Hobernik, Dominika, and Matthias Bros. “DNA Vaccines-How Far From Clinical Use?.”
                                International journal of molecular sciencesvol.19,11 3605. 15 Nov. 2018,
                                doi:10.3390/ijms19113605
                            </p>
                        </li>
                        <li>
                            <p>
                                Tarek, M. (2020, January 1). Custommune: a web tool to design personalized and
                                population-targeted vaccine epitopes. MedRxiv. <br>
                                https://www.medrxiv.org/content/10.1101/2020.04.25.20079426v1
                            </p>
                        </li>
                        <li>
                            <p>
                                Nezafat, Navid, et al. "Designing an efficient multi-epitope oral vaccine against
                                Helicobacter pylori using immunoinformatics and structural vaccinology approaches."
                                Molecular BioSystems 13.4 (2017): 699-713.
                            </p>
                        </li>
                        <li>
                            <p>
                                Parvizpour, Sepideh et al. “In silico design of a triple-negative breast cancer vaccine
                                by targeting cancer testis antigens.” BioImpacts : BI vol. 9,1 (2019): 45-56.
                                doi:10.15171/bi.2019.06
                            </p>
                        </li>
                        <li>
                            <p>
                                Amorim, K., Rampazo, E., Antonialli, R. et al. The presence of T cell epitopes is
                                important for induction of antibody responses against antigens directed to DEC205+
                                dendritic cells. Sci Rep 6, 39250 (2016). https://doi.org/10.1038/srep39250
                            </p>
                        </li>
                        <li>
                            <p>
                                Dar, Hamza Arshad, et al. "Immunoinformatics-Aided Design and Evaluation of a Potential
                                Multi-Epitope Vaccine against Klebsiella Pneumoniae." Vaccines 7.3 (2019): 88.
                            </p>
                        </li>
                        <li>
                            <p>
                                Tang, Mi, et al. "Antitumor efficacy of the Runx2‑dendritic cell vaccine in
                                triple‑negative breast cancer in vitro." Oncology Letters 16.3 (2018): 2813-2822.
                            </p>
                        </li>
                        <li>
                            <p>
                                DNA-launched RNA replicon vaccines induce potent anti-Ebolavirus immune responses that
                                can be further improved by a recombinant MVA boost. (2020, October 25). PubMed
                                Central(PMC). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6102224/"
                                    target="blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6102224/</a>
                            </p>
                        </li>
                        <li>
                            <p>
                                DiAndreth, B. (2019, January 1). PERSIST: A programmable RNA regulation platform using
                                CRISPR endoRNases. BioRxiv. https://www.biorxiv.org/content/10.1101/2019.12.15.867150v1
                            </p>
                        </li>
                        <li>
                            <p>
                                Ossevoort, M. (2003, October 20). Creation of immune ‘stealth’ genes for gene therapy
                                through fusion with the Gly-Ala repeat of
                                EBNA-1.GeneTherapy.
                                https://www.nature.com/articles/3302098?error=cookies_not_supported&code=bb5e8128-3eea-4a9f-aa12-6ffffd0ab55a
                            </p>
                        </li>
                        <li>
                            <p>
                                Multiepitope-Based Subunit Vaccine Design and Evaluation against Respiratory Syncytial
                                Virus Using Reverse Vaccinology Approach. (2020, June 1). PubMed
                                Central (PMC). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350008/
                            </p>
                        </li>
                        <li>
                            <p>
                                http://150.146.2.1/C-IMMSIM/
                            </p>
                        </li>
                    </ol>
                </section>
            </main>




            <footer class="d-flex align-items-end pb-5">
                <div class="container">
                    <div class="row justify-content-between mt-5 pt-5">
                        <div class="col-md-3">
                            <h3>SPONSORS</h3>
                            <div class="d-flex flex-wrap" style="width: 70%;">
                                <div class="sponsor-logo mr-1 mb-1">
                                    <img src="https://2020.igem.org/wiki/images/2/29/T--AFCM-Egypt--Sponsors1.jpeg"
                                        class="rounded-circle" width="35" alt="" />
                                </div>
                                <div class="sponsor-logo mr-1">
                                    <img src="https://2020.igem.org/wiki/images/9/9e/T--AFCM-Egypt--Sponsors2.jpeg"
                                        class="rounded-circle" width="35" alt="" />
                                </div>
                                <div class="sponsor-logo mr-1">
                                    <img src="https://2020.igem.org/wiki/images/4/49/T--AFCM-Egypt--Sponsors3.jpeg"
                                        class="rounded-circle" width="35" alt="" />
                                </div>
                                <div class="sponsor-logo mr-1">
                                    <img src="https://2020.igem.org/wiki/images/4/45/T--AFCM-Egypt--Sponsors4.jpeg"
                                        class="rounded-circle" width="35" alt="" />
                                </div>
                                <div class="sponsor-logo mr-1">
                                    <img src="https://2020.igem.org/wiki/images/1/12/T--AFCM-Egypt--Sponsors5.jpeg"
                                        class="rounded-circle" width="35" alt="" />
                                </div>
                                <div class="sponsor-logo mr-1">
                                    <img src="https://2020.igem.org/wiki/images/0/0a/T--AFCM-Egypt--Sponsors6.jpeg"
                                        class="rounded-circle" width="35" alt="" />
                                </div>
                                <div class="sponsor-logo mr-1">
                                    <img src="https://2020.igem.org/wiki/images/2/26/T--AFCM-Egypt--Sponsors7.jpeg"
                                        class="rounded-circle" width="35" alt="" />
                                </div>
                            </div>
                        </div>
                        <div class="col-md-3 align-items-between">
                            <div class="my-auto">
                                <img src="https://2020.igem.org/wiki/images/5/55/T--AFCM-Egypt--LOGO-BEGIN.png"
                                    width="40%" alt="" />
                                <h4>We Engineer <br />To Clear..</h4>
                            </div>
                            <div class="text-white d-flex align-items-center">
                                <div class="d-inline mr-3">
                                    <svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"
                                        width="25.426" viewBox="0 0 70.426 88">
                                        <defs>
                                            <linearGradient id="linear-gradient" x1="0.49" y1="-0.398" x2="0.508"
                                                y2="1.168" gradientUnits="objectBoundingBox">
                                                <stop offset="0.132" stop-color="#01cf2d" />
                                                <stop offset="0.794" stop-color="#009804" />
                                            </linearGradient>
                                        </defs>
                                        <g id="Groupe_92" data-name="Groupe 92"
                                            transform="translate(-747.027 -6386.493)">
                                            <path id="Tracé_447" data-name="Tracé 447"
                                                d="M817.453,6436.63a35.213,35.213,0,1,1-35.225-35.2A35.222,35.222,0,0,1,817.453,6436.63Z"
                                                fill="url(#linear-gradient)" />
                                            <text id="_" data-name="@" transform="translate(752.197 6457.493)"
                                                fill="#fff" font-size="65.925" font-family="SegoeUI, Segoe UI">
                                                <tspan x="0" y="0">@</tspan>
                                            </text>
                                        </g>
                                    </svg>
                                </div>
                                <small>igem.afcm@gmail.com</small>

                            </div>
                        </div>
                        <div class="col-md-3">
                            <h3 class="mt-5">FOLLOW US</h3>
                            <div class="d-flex justify-content-between" style="width: 50%;">
                                <i class="fa fa-facebook-square" style="font-size: 25px; color: #3b5998	;"
                                    aria-hidden="true"></i>
                                <i class="fa fa-twitter-square" style="font-size: 25px; color: #1da1f2;"
                                    aria-hidden="true"></i>
                                <i class="fa fa-instagram" style="font-size: 25px; color: #8a3ab9;"
                                    aria-hidden="true"></i>

                            </div>
                        </div>
            </footer>
        </div>
    </div>
</body>

</html>